Combioxin is developing a drug for acquired immune deficiency in intensive care patients. Together with the University of Bern, it has secured CHF 1.1 million in non-dilutive support from Innosuisse for this project.
- Announced on
- Round
- Grant
- Amount
- CHF 1.1 M
- Location
- Epalinges, canton of Vaud
- Sector
- Biotech & life sciences
Investors
- Innosuisse lead
Preparing a similar round?
The diagnostic shows you the instruments and investors that fit your stage.
Start the diagnostic